End-of-day quote
New Zealand S.E.
03:30:00 24/05/2024 am IST
5-day change
1st Jan Change
2.91
NZD
-7.32%
+2.11%
-16.86%
AFT Pharmaceuticals : FY22 Results Appendix 2
Results for announcement to the market
AFT Pharmaceuticals Limited
Reporting Period
12 months to 31 March 2022
Previous Reporting Period
12 months to 31 March 2021
Currency
NZ$
Amount (000s)
Percentage change
Revenue from continuing
$130,314
Up 15%
operations
Total Revenue
$130,314
Up 15%
Net profit/(loss) from continuing
$19,848
Up 155%
operations
Total net profit/(loss)
$19,848
Up 155%
Interim/Final Dividend
Quoted Equity Securities:
Amount per Quoted Equity
No dividends have been paid on ordinary shares and it is
Security
currently not proposed to pay dividends.
Imputed amount per Quoted
Not Applicable
Equity Security
Record Date
Not Applicable
Dividend Payment Date
Not Applicable
Current period
Prior comparable period
Net tangible assets per Quoted
$0.18
$0.04
Equity Security
A brief explanation of any of the
Accompanying this announcement are the Group's audited
figures above necessary to
consolidated financial statements for the twelve months
enable the figures to be
ended 31 March 2022. These financial statements and the
understood
full year results commentary dated 23 May 2022 provide the
balance of information requirements in accordance with NZX
Listing Rule 3.5 and Appendix 2.
Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals
Limited confirms that it continues to comply with the rules of
its home exchange (NZX Main Board).
Authority for this announcement
Name of person authorised to
Malcolm Tubby
make this announcement
Contact person for this
Malcolm Tubby, Chief Financial Officer,
announcement
AFT Pharmaceuticals Ltd
Contact phone number
+64 9 488 0232
Contact email address
malcolm@aftpharm.com
Date of release through MAP
23 May 2022
Audited financial statements accompany this announcement.
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969
Attachments
Original Link
Original Document
Permalink
Disclaimer
AFT Pharmaceuticals Limited published this content on 20 May 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 23 May 2022 07:35:06 UTC .
AFT Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024
23/05
CI
Transcript : AFT Pharmaceuticals Limited, 2024 Earnings Call, May 23, 2024
23/05
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared
23/05
MT
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV
01/05
MT
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment
24/04
MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment
24/04
MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment
24/04
CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down
04/03
MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals
04/03
MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals
04/03
CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance
16/02
MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024
16/02
MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024
16/02
CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%
07/02
MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US
06/02
MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication
19/01
MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus
18/01
CI
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate
22/12
MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals
22/12
CI
France keeps 2024 bond issuance steady at 285 bln euros
13/12
RE
AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024
23/11
CI
Transcript : AFT Pharmaceuticals Limited, H1 2024 Earnings Call, Nov 23, 2023
23/11
AFT Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023
23/11
CI
AFT Pharmaceuticals Secures Clearance to Sell Antiseptic Ointment in China
21/11
MT
Hyloris Pharma wins US FDA approval for pain treatment
18/23/18
RE
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
More about the company
Last Close Price
2.91
NZD
Average target price
3.75
NZD
Spread / Average Target
+28.87%
Consensus
1st Jan change
Capi.
-16.86% 19Cr +38.51% 73TCr +33.05% 60TCr -6.23% 35TCr +18.78% 33TCr +1.35% 28TCr +16.00% 24TCr +8.09% 20TCr -5.77% 20TCr +6.19% 16TCr
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1